Physician profile
Amber Kyle
NPI 1326123233
$850.13
in general payments reported to CMS, 2019-2025
14 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.16 · 2020: $26.56 · 2021: $49.35 · 2022: $47.57 · 2023: $171 · 2024: $257 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $181.34 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $171.57 | 2022-2024 | |
| Ani Pharmaceuticals, INC. | $124.37 | 2025 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $69.96 | 2024 | Sotyktu |
| Abbvie INC. | $49.78 | 2020-2021 | |
| Pfizer INC. | $46.42 | 2021-2023 | |
| Amgen INC. | $38.00 | 2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $35.77 | 2025 | Dupixent |
| Lilly USA, LLC | $32.46 | 2025 | Zepbound, Ebglyss, Taltz |
| Novartis Pharmaceuticals Corporation | $31.13 | 2024 | |
| Organon LLC | $25.48 | 2025 | Vtama |
| Journey Medical Corporation | $16.89 | 2023 | |
| Ucb, INC. | $14.80 | 2024 | Bimzelx |
| Allergan, INC. | $12.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Kyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.